Figure 2From: Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver diseaseOverall summary of meta-analyses results of treatments of pentoxifylline for NASH. Pentoxifylline-treated patients showed a significant decrease AST (n = 37, P = 0.01) and ALT (n = 50, P = 0.03), but no significant effect on IL-6 (n = 36, P = 0.33) and TNF-α (n = 68, P = 0.26) compared with Placebo or UDCA-controlled groups.Back to article page